Progress in management of thyroid eye disease (TED) has been slow for many decades.
The recent introduction of teprotumumab (TEP) in the therapeutic arena for TED has had a …

In this study, we conducted a meta‐analysis to assess the efficacy and safety of
teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed …

Teprotumumab (TEPEZZA®), a monoclonal antibody that inhibits the insulin-like growth
factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment …

Background: Thyroid eye disease (TED) is a vision-threatening and debilitating condition
that until very recently had no Food and Drug Administration (FDA)-approved medical …

Teprotumumab, a monoclonal antibody targeted against the insulin-like growth factor 1 (IGF-
1) receptor, was recently approved by the United States Food and Drug Administration for …

Introduction Thyroid eye disease (TED) is an autoimmune disease characterized by
inflammation of orbital and extraocular muscles. It induces proptosis and diplopia, leading to …

The arrival of teprotumumab has been hailed as a gamechanger in the treatment of thyroid
eye disease (TED). 1 This monoclonal antibody to the insulin-like growth factor-1 receptor is …

Background: Teprotumumab is the first treatment for thyroid eye disease (TED), a debilitating
autoinflammatory condition, approved by the Food and Drug Administration in the United …

Introduction: Thyroid eye disease (TED) is an autoimmune process characterized by
extraocular muscle and orbital fat remodeling/expansion resulting in swelling, pain, redness …

Thyroid eye disease (TED) is a chronic inflammatory condition that can lead to permanent
disfigurement, disability, and vision loss. It is traditionally believed that TED is a self-limited …